• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JCI Insight Clinical and Pathological Investigation of Severe COVID-19 Patients

tetano

Editor, Senior Moderator
JCI Insight


. 2020 May 19;138070.
doi: 10.1172/jci.insight.138070. Online ahead of print.
Clinical and Pathological Investigation of Severe COVID-19 Patients


Shaohua Li[SUP] 1 [/SUP], Lina Jiang[SUP] 1 [/SUP], Xi Li[SUP] 1 [/SUP], Fang Lin[SUP] 2 [/SUP], Yijin Wang[SUP] 1 [/SUP], Boan Li[SUP] 3 [/SUP], Tianjun Jiang[SUP] 4 [/SUP], Weimin An[SUP] 5 [/SUP], Shuhong Liu[SUP] 1 [/SUP], Hongyang Liu[SUP] 1 [/SUP], Pengfei Xu[SUP] 1 [/SUP], Lihua Zhao[SUP] 1 [/SUP], Lixin Zhang[SUP] 1 [/SUP], Jinsong Mu[SUP] 2 [/SUP], Hongwei Wang[SUP] 6 [/SUP], Jiarui Kang[SUP] 6 [/SUP], Yan Li[SUP] 1 [/SUP], Lei Huang[SUP] 4 [/SUP], Caizhong Zhu[SUP] 4 [/SUP], Shousong Zhao[SUP] 7 [/SUP], Jiangyang Lu[SUP] 6 [/SUP], Junsheng Ji[SUP] 4 [/SUP], Jingmin Zhao[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Severe acute respiratory coronavirus 2 (SARS-CoV-2) caused coronavirus disease 2019 (COVID-19) has become a pandemic. This study addressed the clinical and immunopathological characteristics of severe COVID-19.
Methods: Sixty-nine COVID-19 patients were classified into as severe and non-severe groups to analyze their clinical and laboratory characteristics. A panel of blood cytokines was quantified over time. Biopsy specimens from two deceased cases were obtained for immunopathological, ultrastructural, and in situ hybridization examinations.
Results: Circulating cytokines, including IL8, IL6, TNFα, IP10, MCP1, and RANTES, were significantly elevated in severe COVID-19 patients. Dynamic IL6 and IL8 were associated with disease progression. SARS-CoV-2 was demonstrated to infect type II, type I pneumocytes and endothelial cells, leading to severe lung damage through cell pyroptosis and apoptosis. In severe cases, lymphopenia, neutrophilia, depletion of CD4+ and CD8+ T lymphocytes, and massive macrophage and neutrophil infiltrates were observed in both blood and lung tissues.
Conclusions: A panel of circulating cytokines could be used to predict disease deterioration and inform clinical interventions. Severe pulmonary damage was predominantly attributed to both SARS-CoV-2 caused cytopathy and immunopathologic damage. Strategies that encourage pulmonary recruitment and overactivation of inflammatory cells by suppressing cytokine storm might improve the outcomes of severe COVID-19 patients.

Keywords: Apoptosis; Infectious disease; Macrophages; Medical statistics; Pulmonology.
 
Back
Top Bottom